YIFAN PHARMACEUTICAL CO LTD - Class A

SZSE:002019 (China)   Class A
Â¥ 12.51 (-1.73%) Jun 20
At Loss
P/B:
1.82
Market Cap:
Â¥ 15.34B ($ 2.11B)
Enterprise V:
Â¥ 16.78B ($ 2.31B)
Volume:
5.90M
Avg Vol (2M):
10.86M
Trade In:
Volume:
5.90M
At Loss
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for YIFAN PHARMACEUTICAL CO LTD ( SZSE:002019 ) from 2004 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. YIFAN PHARMACEUTICAL stock (SZSE:002019) PE ratio as of Jun 20 2024 is 0. More Details

YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) PE Ratio (TTM) Chart

To

YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) PE Ratio (TTM) Historical Data

Total 1208
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
YIFAN PHARMACEUTICAL PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-20 At Loss 2024-04-12 At Loss
2024-06-19 At Loss 2024-04-11 At Loss
2024-06-18 At Loss 2024-04-10 At Loss
2024-06-17 At Loss 2024-04-09 At Loss
2024-06-14 At Loss 2024-04-08 At Loss
2024-06-13 At Loss 2024-04-03 At Loss
2024-06-12 At Loss 2024-04-02 At Loss
2024-06-11 At Loss 2024-04-01 At Loss
2024-06-07 At Loss 2024-03-29 At Loss
2024-06-06 At Loss 2024-03-28 At Loss
2024-06-05 At Loss 2024-03-27 At Loss
2024-06-04 At Loss 2024-03-26 At Loss
2024-06-03 At Loss 2024-03-25 At Loss
2024-05-31 At Loss 2024-03-22 At Loss
2024-05-30 At Loss 2024-03-21 At Loss
2024-05-29 At Loss 2024-03-20 At Loss
2024-05-28 At Loss 2024-03-19 At Loss
2024-05-27 At Loss 2024-03-18 At Loss
2024-05-24 At Loss 2024-03-15 At Loss
2024-05-23 At Loss 2024-03-14 At Loss
2024-05-22 At Loss 2024-03-13 At Loss
2024-05-21 At Loss 2024-03-12 At Loss
2024-05-20 At Loss 2024-03-11 At Loss
2024-05-17 At Loss 2024-03-08 At Loss
2024-05-16 At Loss 2024-03-07 At Loss
2024-05-15 At Loss 2024-03-06 At Loss
2024-05-14 At Loss 2024-03-05 At Loss
2024-05-13 At Loss 2024-03-04 At Loss
2024-05-10 At Loss 2024-03-01 At Loss
2024-05-09 At Loss 2024-02-29 At Loss
2024-05-08 At Loss 2024-02-28 At Loss
2024-05-07 At Loss 2024-02-27 At Loss
2024-05-06 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-08 At Loss
2024-04-22 At Loss 2024-02-07 At Loss
2024-04-19 At Loss 2024-02-06 At Loss
2024-04-18 At Loss 2024-02-05 At Loss
2024-04-17 At Loss 2024-02-02 At Loss
2024-04-16 At Loss 2024-02-01 At Loss
2024-04-15 At Loss 2024-01-31 At Loss

YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.